Workshop report: Crystal City V--quantitative bioanalytical method validation and implementation: the 2013 revised...

Area of Science:

• Pharmaceutical Sciences
• Regulatory Science
• Biotechnology

Background:

• The U.S. Food and Drug Administration (FDA) issued a draft revision to the Bioanalytical Method Validation (BMV) Guidance in September 2013.
• This revision introduced significant changes, notably the inclusion of biomarker assays and associated data within bioanalytical expectations.

Purpose of the Study:

• To facilitate open discussion and gather feedback on the revised BMV Guidance draft.
• To provide a collaborative platform for regulatory agencies and industry stakeholders.

Main Methods:

• A two-and-a-half-day workshop was jointly organized by the American Association of Pharmaceutical Scientists (AAPS) and the FDA in December 2013.
• The workshop featured four thematic sessions (Common Topics, Chromatographic, Ligand-Binding Assays, Biomarkers) and a session with international regulators, emphasizing open discussion over lengthy presentations.

Main Results:

• The workshop summarized outcomes, including areas of consensus between the FDA and industry.
• Identified topics where the FDA will consider industry perspectives and areas requiring further dialogue were noted.
• Recommendations stemming from the thematic sessions and the international regulator session were compiled.

Conclusions:

• The workshop successfully initiated dialogue on the revised BMV Guidance, particularly concerning biomarker bioanalysis.
• Outcomes provide valuable insights for the finalization of the BMV Guidance and future bioanalytical practices.